The Valley

Researchers in Chile proved a hantavirus vaccine worked.

This is the difficult part of vaccine development. The science. The human trials. Demonstrating that a disease killing 35 to 40 percent of everyone it infects can be stopped, safely, in people. They did that. The vaccine was safe. The vaccine was effective. The vaccine went into the Valley of Death.

The Valley of Death is not a geographic location. It is the funding gap between "we proved it works" and "anyone will make it." It sits between clinical trials and commercial production. Scientists named it. They use the name professionally, in academic papers and grant applications, without apparent irony, because after a certain number of cures die in it, irony becomes unavailable.

(The phrase "Valley of Death" appears in scientific literature as a technical term. The first time you read it, you assume it is someone's dark joke. It is not. It is a category.)

The reason cures die in the Valley is not that the cures don't work. It is that hantavirus does not infect enough people to make the cure profitable to manufacture. The economics of infectious disease: the cure has to generate more revenue than the disease costs. If the disease only kills a few thousand people, the math does not work. The cure goes in the Valley. The cure stays there.

The researchers are aware of the math. They proved the vaccine worked anyway. The vaccine is still in the Valley.

The hantavirus is not in the Valley. The hantavirus is in Canada now.